Washington, DC (PRWEB) November 14, 2012
The editorial team at FierceBiotech today announced its executive breakfast being held in San Francisco during the week of the J.P. Morgan Healthcare Conference. The event, Big Data Biopharma Forum (http://www.fiercebiotech.com/events/big-data-biopharma-forum/2013) will be held at the Hotel Nikko in San Francisco, CA (222 Mason Street) from 7:30—9:00AM on January 9, 2013.
The current roster of speakers includes John Reynders, Vice President of R&D Information at AstraZeneca; Dr. Lon Cardon, Senior Vice President, GlaxoSmithKline; David Mott, General Partner, New Enterprise Associates, and former CEO of MedImmune; and Alexis Borisy, Partner at Third Rock Ventures. The event will be structured as an open roundtable discussion focusing on the impact of Big Data on bipharma’s operations and investment plans. The conversation will explore the current and future impacts of Big Data in drug development along with potential implications for advancing drug research with new IT advances.
“We're thrilled about the diverse panel of speakers we’ve assembled for this event,” said FierceBiotech Executive Editor, Ryan McBride, who will also moderate the roundtable. "The unscripted, open dialogue created by an event of this nature provides attendees with a unique opportunity to hear what top executives really have to say about the issues they face.”
Registration for the event is now open. Additional event information, including secure online registration, can be found at http://www.fiercebiotech.com/events/big-data-biopharma-forum/2013. An early bird of $69 is currently available through November 30.
The event is currently being sponsored by Synteract. For additional information about sponsorship opportunities associated with the event, contact Rebecca Friend at 202-824-5050 or rfriend (at) fiercemarkets (dot) com.
Fierce’s portfolio of life sciences titles reaches more than 416,000 readers and includes FierceBiomarkers; FierceBiotech; FierceBiotech Research; FierceBiotechIT; FierceCRO; FierceDrugDelivery; FierceMedicalDevices; FiercePharma; FiercePharmaManufacturing; and FierceVaccines